Investical Earnings & investing calendar Earnings & investing calendar
/
AASKA Pharmaceutical Holdings Co.,Ltd. logo
4886TSE Prime

ASKA Pharmaceutical Holdings Co.,Ltd.

あすか製薬ホールディングス Yahoo Finance

Recent & upcoming events

Sep 28
Ex-dividend Time TBD
Ex-rights date (interim)
Add to Google Calendar
Sep 27
Dividend Time TBD
Last day with rights (interim)
Add to Google Calendar
Aug 4
Earnings 2:00
Q1 earnings announcement (scheduled)
Add to Google Calendar
Jun 23
Shareholder meeting Time TBD
Shareholders' meeting
Add to Google Calendar
Nov 4
Earnings 1:00 approx.
Q2 earnings announcement (scheduled)
Add to Google Calendar
2027
Feb 3
Est.
Earnings 1:00 approx.
Earnings announcement (predicted)
Add to Google Calendar
Mar 28
Est.
Dividend Time TBD
Last day with rights (year-end)
Add to Google Calendar
Mar 29
Est.
Ex-dividend Time TBD
Ex-rights date (year-end)
Add to Google Calendar
May 5
Est.
Earnings 2:00 approx.
Earnings announcement (predicted)
Add to Google Calendar
Aug 4
Est.
Earnings 2:00 approx.
Earnings announcement (predicted)
Add to Google Calendar
Sep 27
Est.
Dividend Time TBD
Last day with rights (interim)
Add to Google Calendar
Sep 28
Est.
Ex-dividend Time TBD
Ex-rights date (interim)
Add to Google Calendar
Nov 10
Est.
Earnings 1:00 approx.
Earnings announcement (predicted)
Add to Google Calendar

KPI highlights

FY26
Revenue ¥71.13B YoY +10.9%
Operating income ¥5.83B margin 8.2%
Net income ¥5.42B YoY +6.3%
EPS ¥191 YoY +6.2%
P/E —
ROE 8.0% Equity ratio 63% Typical equity ratios vary a lot by industry. Banks, brokerages, and other financial companies tend to run lower ratios because leverage (using other people's capital) is core to their business model — a low ratio there isn't a sign of financial weakness.

Company guidance

FY2027/03 Company-issued full-year guidance (from earnings report) / %=vs prior FY
Revenue ¥73.00B +2.6%
Operating income ¥6.20B +6.3%
Net income ¥4.80B -11.5%
EPS ¥169 -11.5%

Quarterly fundamentals

Income & cash flow
Quarter FY23 Q2FY23 Q3FY23 Q4FY24 Q1FY24 Q2FY25 Q2
Revenue ¥16.02B¥15.63B¥17.18B¥14.02B——
Operating income ¥1.70B¥1.35B¥2.47B¥973M——
Net income ¥1.43B¥2.70B¥2.33B¥1.09B——
Operating CF ——————

Ownership over time

Share of total shares outstanding (disclosed major holdings + undisclosed)（2022–2026）

事業法人 14.4%国内機関 13.3%海外機関 11.8%アクティビスト 8.4%未開示 49.6%20222023202420252026
事業法人国内機関海外機関アクティビスト個人未開示・浮動株

「国内機関」は信託銀行の名義口座（年金・パッシブ・一部海外資本を含む）を集計し、実質保有者へは分解していません。分類は開示名称からの推定です。

Top shareholders — rank & share

日本マスタートラスト信託銀行株式会社 9.4%日本マスタートラスト信託銀行株式会社（信託口）NIPPON ACTIVE VALU 8.4%NIPPON ACTIVE VALUE FUND PLC（常任代理人 香港上海銀行東京支店）武田薬品工業株式会社 7.8%武田薬品工業株式会社ゼリア新薬工業株式会社 6.6%ゼリア新薬工業株式会社STATE STREET BANK 4%STATE STREET BANK AND TRUST COMPANY 505103（常任代理人 株式会社みずほ銀行決済営業部）株式会社三菱ＵＦＪ銀行 3.9%株式会社三菱ＵＦＪ銀行NAVF SELECT LLC（常任 3%NAVF SELECT LLC（常任代理人 香港上海銀行東京支店）山口隆 2.5%山口隆20222023202420252026

Top shareholders — actual figures (as of 2026)

Holder Shares held Ratio Source
日本マスタートラスト信託銀行株式会社（信託口） 2,670,000 9.4% Yuho (EDINET)
NIPPON ACTIVE VALUE FUND PLC 2,399,000 8.4% Yuho (EDINET)
武田薬品工業株式会社 2,204,000 7.8% Yuho (EDINET)
ゼリア新薬工業株式会社 1,877,000 6.6% Yuho (EDINET)
STATE STREET BANK AND TRUST COMPANY 505103 1,138,000 4.0% Yuho (EDINET)
株式会社三菱UFJ銀行 1,100,000 3.9% Yuho (EDINET)
NAVF SELECT LLC 848,000 3.0% Yuho (EDINET)
NOMURA PB NOMINEES LIMITED OMNIBUS MARGIN（CASHPB） 789,000 2.8% Yuho (EDINET)
山口隆 707,000 2.5% Yuho (EDINET)
CACEIS BANK,LUXEMBOURG BRANCH/AIF CLIENTS ASSETS 593,000 2.1% Yuho (EDINET)

Source：EDINET（大株主の状況）　Classification inferred from disclosed names

F-Score (Piotroski)

5/9

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

✓ Positive ROA ROA 4.8%
✓ Positive operating cash flow ¥6.30B
✗ ROA improved YoY 5.1% → 4.8%
✓ Operating CF exceeds net income (accrual quality) OCF ¥6.30B / net income ¥5.42B
✗ Equity ratio improved* Substitute for the original “decrease in long-term debt” 65.0% → 62.6%
✓ Current ratio improved 2.54× → 2.76×
✓ No dilution (shares outstanding did not increase) 28,763,199 → 28,763,199
✗ Gross margin improved 48.9% → 48.0%
✗ Asset turnover improved 0.64× → 0.63×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY26
Equity ratio 62.6%
Current ratio 2.8×
Years of positive operating CF 5 of last 5 yrs
Payout ratio 71%
Latest fiscal year result Profit (net income ¥5.42B)

Performance history

Last 10 years
0億円178億円356億円533億円711億円 FY22FY23FY24FY25FY26

Income & assets

Unit: ¥100M
Item FY22FY23FY24FY25FY26
Revenue 566605628641711
Operating income 48.051.165.053.358.3
Ordinary income 48.852.365.251.156.7
Net income 42.942.475.551.054.2
Total assets 8338719071,0051,124
Equity 489545619692768

Indicators & cash flow

Unit: ¥100M
Item FY22FY23FY24FY25FY26
EPS ¥151¥150¥267¥180¥191
ROE 8.8%8.2%13.0%8.0%8.0%
Operating CF 28.433.514.924.963.0
Investing CF 67.4-11.317.1-61.2-57.5
Financing CF -30.0-18.2-39.4-29.6-8.18
FCF 95.922.331.9-36.45.51

Source: EDINET (Annual Securities Report) (fetched 2026-08-29) *Some metrics supplemented from additional sources

Key financial metrics

3-year revenue growth ✓ Dividend grower ✓

Sector positioning

Relative standing within the sector
Is this information incorrect?

Data provided by Twelve Data